Upcoming Medical Conferences in DoylestownSearch Criteria : United States of America Doylestown
Sep 13 - 14, 2019 | Contact Ho 13.00 | USD $435 | Doylestown, Pennsylvania
Rehabilitative Management of Patients with Neurodegenerative Conditions - Session 2 is organized by Sep 13 - 14, 2019 at Doylestown Health: Doylestown Hospital, Doylestown, Pennsylvania, United States of America. Audience: PTs, PTAs, OTs, COTAs and SLPs involved in the care of patients with neurodegenerative conditions, ranging from young adults to geriatric patients Credits: This course meets the criteria for 13 contact hours (1.3 CEUs). Application has been made to the MD and NJ Board of PT Examiners. The DC, DE, PA and VA Boards of Physical Therapy accept other board's approval. TX PT Association approved provider. This course meets the approval for Type 2 CEUs by the TX Board of Occupational Therapy Examiners. Approved provider by the NY State Board of Physical Therapy for 15.6 contact hours Approved provider of continuing education b y t h e A m e r i c a n O c c u p a t i o n a l Therapy Association #3043, for 13 contact hours - Intermediate Level Occupational Therapy Process: assessment, intervention. The assignment of AOTA CEU's does not imply endorsement of specific course content, products or clinical procedures by AOTA. This program has been submitted for approval of 13 clock hours of continuing education by the TX SpeechLanguage-hearing Association (TSHA) NBCOT Professional Development Provider - 13 PDU's This course is offered for up to 1.3 ASHA CEUs (Intermediate level, Professional area). Course Description: How do you define success in treatment of a progressive condition? Neurodegenerative conditions such as Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington’s disease present individuals with new, often worsening, impairments as the conditions progress. While it may come off as a daunting task, rehabilitation professionals play a crucial role in addressing the ‘now’ and preparing for the ‘what if.’ Specific motor impairments, such as freezing of gait in Parkinson’s disease or spasticity in multiple sclerosis, provide unique challenges to mobility and daily activities. Not only are there physical signs we must address in therapy services, but also the non-motor impairments. Oftentimes decreased attention, difficulty multitasking, and behavioral barriers limit our ability to maintain or improve a patient’s functional status. This course aims to improve clinician skills from diagnosis through late-stage disease management. Literature review, video case studies, and group discussions will be useful in building your skills. Improved understanding of diagnoses, pathologies, and medical management is necessary when considering the clinical decision-making process. This information leads us to define appropriate goals, apply evidence-based interventions, and care for all of the complexities that come along with an uphill battle against neurodegeneration. Course Objectives: At the end of day one, attendees should be able to: • Summarize fundamentals of pathology associated with Parkinson’s disease (PD), secondary parkinsonisms, and atypical parkinsonisms • Recognize clinical signs and symptoms of PD and parkinsonisms ○ Classify motor and non-motor signs of PD and parkinsonisms ○ Differentiate various cognitive impairments and their impact on functional mobility • Summarize the mechanism of action, clinical candidacy, and common side effects of disease-specific medications of PD • Identify appropriate outcome measures related to disease-specific impairments of PD • Apply research-based interventions for PD and parkinsonisms • Conceptualize long-term management of patients with parkinsonism through all therapy services and community-based programs At the end of day two, attendees should be able to: • Summarize fundamentals of pathology associated with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD) • Recognize clinical signs and symptoms of MS, ALS, and HD • Summarize the mechanism of action, clinical candidacy, and common side effects of disease-specific medications of MS, ALS, and HD • Identify appropriate outcome measures and interventions related to disease-specific impairments of MS, ALS, and HS • Explain factors that influence the prescription and use of equipment and assistive technology in patients with neurodegenerative conditions Additional details will be posted as soon as they are available.